Provided are an injectable intraocular microgel and an injectable intraocular hydrogel that are safe to a human body and that can release a drug in the eye for a long period of time. This injectable intraocular microgel may have a form in which a drug is loaded on a hyaluronic acid microgel generated by causing hyaluronic acid copolymers to cross-link with each other through a w/o emulsion method.

Described herein are anti-angiopoictin-like 4 (ANGPTL4) antibodies and methods of treating disorders associated with elevated expression of ANGPTL4. In one aspect, described herein is an antibody or antigen binding fragment thereof that binds angiopoietin-like 4 (ANGPTL4) comprising amino acid sequences set forth in (a) SEQ ID NOs: 3-8 (Ab-A CDRs), (b) SEQ ID NOs: 13-18 (Ab-B CDRs), (c) SEQ ID NOs: 23-28 (Ab-C CDRs), (d) SEQ ID NOs: 33-38 (Ab-D CDRs), or (e) SEQ ID NOs: 43-48 (Ab-E CDRs).

Described herein are anti-angiopoictin-like 4 (ANGPTL4) antibodies and methods of treating disorders associated with elevated expression of ANGPTL4. In one aspect, described herein is an antibody or antigen binding fragment thereof that binds angiopoietin-like 4 (ANGPTL4) comprising amino acid sequences set forth in (a) SEQ ID NOs: 3-8 (Ab-A CDRs), (b) SEQ ID NOs: 13-18 (Ab-B CDRs), (c) SEQ ID NOs: 23-28 (Ab-C CDRs), (d) SEQ ID NOs: 33-38 (Ab-D CDRs), or (e) SEQ ID NOs: 43-48 (Ab-E CDRs).

Multispecific antagonists for targeting angiogenesis pathways are disclosed. The multispecific antagonists may be used for the treatment of disorders associated with angiogenesis pathways.

Multispecific antagonists for targeting angiogenesis pathways are disclosed. The multispecific antagonists may be used for the treatment of disorders associated with angiogenesis pathways.

The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.

Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.